Global Peptide Modification Service Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Peptide Modification Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Peptide Modification Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 N-Terminal Modifications
1.2.3 C-Terminal Modifications
1.2.4 Fluorescence Dye Labeling
1.2.5 Phosphorylation
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Peptide Modification Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Commercial
1.3.3 Academic Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Peptide Modification Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Peptide Modification Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Peptide Modification Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Peptide Modification Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 N-Terminal Modifications Market Size by Players
3.3.2 C-Terminal Modifications Market Size by Players
3.3.3 Fluorescence Dye Labeling Market Size by Players
3.3.4 Phosphorylation Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Peptide Modification Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Peptide Modification Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Peptide Modification Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Peptide Modification Service Market Size by Type (2020-2031)
6.4 North America Peptide Modification Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Peptide Modification Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Peptide Modification Service Market Size by Type (2020-2031)
7.4 Europe Peptide Modification Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Peptide Modification Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Peptide Modification Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Peptide Modification Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Peptide Modification Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Peptide Modification Service Market Size by Type (2020-2031)
9.4 Central and South America Peptide Modification Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Peptide Modification Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Peptide Modification Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Peptide Modification Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Peptide Modification Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GenScript
11.1.1 GenScript Corporation Information
11.1.2 GenScript Business Overview
11.1.3 GenScript Peptide Modification Service Product Features and Attributes
11.1.4 GenScript Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.1.5 GenScript Peptide Modification Service Revenue by Product in 2024
11.1.6 GenScript Peptide Modification Service Revenue by Application in 2024
11.1.7 GenScript Peptide Modification Service Revenue by Geographic Area in 2024
11.1.8 GenScript Peptide Modification Service SWOT Analysis
11.1.9 GenScript Recent Developments
11.2 Biosynth
11.2.1 Biosynth Corporation Information
11.2.2 Biosynth Business Overview
11.2.3 Biosynth Peptide Modification Service Product Features and Attributes
11.2.4 Biosynth Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.2.5 Biosynth Peptide Modification Service Revenue by Product in 2024
11.2.6 Biosynth Peptide Modification Service Revenue by Application in 2024
11.2.7 Biosynth Peptide Modification Service Revenue by Geographic Area in 2024
11.2.8 Biosynth Peptide Modification Service SWOT Analysis
11.2.9 Biosynth Recent Developments
11.3 Bio-Synthesis
11.3.1 Bio-Synthesis Corporation Information
11.3.2 Bio-Synthesis Business Overview
11.3.3 Bio-Synthesis Peptide Modification Service Product Features and Attributes
11.3.4 Bio-Synthesis Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.3.5 Bio-Synthesis Peptide Modification Service Revenue by Product in 2024
11.3.6 Bio-Synthesis Peptide Modification Service Revenue by Application in 2024
11.3.7 Bio-Synthesis Peptide Modification Service Revenue by Geographic Area in 2024
11.3.8 Bio-Synthesis Peptide Modification Service SWOT Analysis
11.3.9 Bio-Synthesis Recent Developments
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Corporation Information
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Peptide Modification Service Product Features and Attributes
11.4.4 Thermo Fisher Scientific Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.4.5 Thermo Fisher Scientific Peptide Modification Service Revenue by Product in 2024
11.4.6 Thermo Fisher Scientific Peptide Modification Service Revenue by Application in 2024
11.4.7 Thermo Fisher Scientific Peptide Modification Service Revenue by Geographic Area in 2024
11.4.8 Thermo Fisher Scientific Peptide Modification Service SWOT Analysis
11.4.9 Thermo Fisher Scientific Recent Developments
11.5 Syd Labs
11.5.1 Syd Labs Corporation Information
11.5.2 Syd Labs Business Overview
11.5.3 Syd Labs Peptide Modification Service Product Features and Attributes
11.5.4 Syd Labs Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.5.5 Syd Labs Peptide Modification Service Revenue by Product in 2024
11.5.6 Syd Labs Peptide Modification Service Revenue by Application in 2024
11.5.7 Syd Labs Peptide Modification Service Revenue by Geographic Area in 2024
11.5.8 Syd Labs Peptide Modification Service SWOT Analysis
11.5.9 Syd Labs Recent Developments
11.6 JPT
11.6.1 JPT Corporation Information
11.6.2 JPT Business Overview
11.6.3 JPT Peptide Modification Service Product Features and Attributes
11.6.4 JPT Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.6.5 JPT Recent Developments
11.7 LifeTein
11.7.1 LifeTein Corporation Information
11.7.2 LifeTein Business Overview
11.7.3 LifeTein Peptide Modification Service Product Features and Attributes
11.7.4 LifeTein Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.7.5 LifeTein Recent Developments
11.8 Creative Peptides
11.8.1 Creative Peptides Corporation Information
11.8.2 Creative Peptides Business Overview
11.8.3 Creative Peptides Peptide Modification Service Product Features and Attributes
11.8.4 Creative Peptides Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.8.5 Creative Peptides Recent Developments
11.9 Elabscience
11.9.1 Elabscience Corporation Information
11.9.2 Elabscience Business Overview
11.9.3 Elabscience Peptide Modification Service Product Features and Attributes
11.9.4 Elabscience Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.9.5 Elabscience Recent Developments
11.10 Genosphere Biotechnologies
11.10.1 Genosphere Biotechnologies Corporation Information
11.10.2 Genosphere Biotechnologies Business Overview
11.10.3 Genosphere Biotechnologies Peptide Modification Service Product Features and Attributes
11.10.4 Genosphere Biotechnologies Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 ProSci
11.11.1 ProSci Corporation Information
11.11.2 ProSci Business Overview
11.11.3 ProSci Peptide Modification Service Product Features and Attributes
11.11.4 ProSci Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.11.5 ProSci Recent Developments
11.12 Giotto Biotech
11.12.1 Giotto Biotech Corporation Information
11.12.2 Giotto Biotech Business Overview
11.12.3 Giotto Biotech Peptide Modification Service Product Features and Attributes
11.12.4 Giotto Biotech Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.12.5 Giotto Biotech Recent Developments
11.13 SB-PEPTIDE
11.13.1 SB-PEPTIDE Corporation Information
11.13.2 SB-PEPTIDE Business Overview
11.13.3 SB-PEPTIDE Peptide Modification Service Product Features and Attributes
11.13.4 SB-PEPTIDE Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.13.5 SB-PEPTIDE Recent Developments
11.14 Biomatik
11.14.1 Biomatik Corporation Information
11.14.2 Biomatik Business Overview
11.14.3 Biomatik Peptide Modification Service Product Features and Attributes
11.14.4 Biomatik Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.14.5 Biomatik Recent Developments
11.15 allele life sciences
11.15.1 allele life sciences Corporation Information
11.15.2 allele life sciences Business Overview
11.15.3 allele life sciences Peptide Modification Service Product Features and Attributes
11.15.4 allele life sciences Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.15.5 allele life sciences Recent Developments
11.16 Synpeptide
11.16.1 Synpeptide Corporation Information
11.16.2 Synpeptide Business Overview
11.16.3 Synpeptide Peptide Modification Service Product Features and Attributes
11.16.4 Synpeptide Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.16.5 Synpeptide Recent Developments
11.17 Omizzur
11.17.1 Omizzur Corporation Information
11.17.2 Omizzur Business Overview
11.17.3 Omizzur Peptide Modification Service Product Features and Attributes
11.17.4 Omizzur Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.17.5 Omizzur Recent Developments
11.18 KMD Bioscience
11.18.1 KMD Bioscience Corporation Information
11.18.2 KMD Bioscience Business Overview
11.18.3 KMD Bioscience Peptide Modification Service Product Features and Attributes
11.18.4 KMD Bioscience Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.18.5 KMD Bioscience Recent Developments
11.19 Leadgene Biomedical
11.19.1 Leadgene Biomedical Corporation Information
11.19.2 Leadgene Biomedical Business Overview
11.19.3 Leadgene Biomedical Peptide Modification Service Product Features and Attributes
11.19.4 Leadgene Biomedical Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.19.5 Leadgene Biomedical Recent Developments
11.20 KenPeptide
11.20.1 KenPeptide Corporation Information
11.20.2 KenPeptide Business Overview
11.20.3 KenPeptide Peptide Modification Service Product Features and Attributes
11.20.4 KenPeptide Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.20.5 KenPeptide Recent Developments
11.21 CASLO
11.21.1 CASLO Corporation Information
11.21.2 CASLO Business Overview
11.21.3 CASLO Peptide Modification Service Product Features and Attributes
11.21.4 CASLO Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.21.5 CASLO Recent Developments
11.22 TGpeptide
11.22.1 TGpeptide Corporation Information
11.22.2 TGpeptide Business Overview
11.22.3 TGpeptide Peptide Modification Service Product Features and Attributes
11.22.4 TGpeptide Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.22.5 TGpeptide Recent Developments
11.23 Boston Cellron
11.23.1 Boston Cellron Corporation Information
11.23.2 Boston Cellron Business Overview
11.23.3 Boston Cellron Peptide Modification Service Product Features and Attributes
11.23.4 Boston Cellron Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.23.5 Boston Cellron Recent Developments
11.24 Bio Basic
11.24.1 Bio Basic Corporation Information
11.24.2 Bio Basic Business Overview
11.24.3 Bio Basic Peptide Modification Service Product Features and Attributes
11.24.4 Bio Basic Peptide Modification Service Revenue and Gross Margin (2020-2025)
11.24.5 Bio Basic Recent Developments
12 Peptide Modification ServiceIndustry Chain Analysis
12.1 Peptide Modification Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Peptide Modification Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Peptide Modification Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Peptide Modification Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Peptide Modification Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Peptide Modification Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Peptide Modification Service Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Peptide Modification Service Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Peptide Modification Service Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Peptide Modification Service Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Peptide Modification Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Modification Service as of 2024)
Table 11. Global Peptide Modification Service Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Peptide Modification Service Companies Headquarters
Table 13. Global Peptide Modification Service Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Peptide Modification Service Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Peptide Modification Service Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Peptide Modification Service Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Peptide Modification Service Revenue by Application (2026-2031) & (US$ Million)
Table 21. Peptide Modification Service High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Peptide Modification Service Growth Accelerators and Market Barriers
Table 25. North America Peptide Modification Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Peptide Modification Service Growth Accelerators and Market Barriers
Table 27. Europe Peptide Modification Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Peptide Modification Service Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Peptide Modification Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Peptide Modification Service Investment Opportunities and Key Challenges
Table 31. Central and South America Peptide Modification Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Peptide Modification Service Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Peptide Modification Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. GenScript Corporation Information
Table 35. GenScript Description and Major Businesses
Table 36. GenScript Product Features and Attributes
Table 37. GenScript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. GenScript Revenue Proportion by Product in 2024
Table 39. GenScript Revenue Proportion by Application in 2024
Table 40. GenScript Revenue Proportion by Geographic Area in 2024
Table 41. GenScript Peptide Modification Service SWOT Analysis
Table 42. GenScript Recent Developments
Table 43. Biosynth Corporation Information
Table 44. Biosynth Description and Major Businesses
Table 45. Biosynth Product Features and Attributes
Table 46. Biosynth Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Biosynth Revenue Proportion by Product in 2024
Table 48. Biosynth Revenue Proportion by Application in 2024
Table 49. Biosynth Revenue Proportion by Geographic Area in 2024
Table 50. Biosynth Peptide Modification Service SWOT Analysis
Table 51. Biosynth Recent Developments
Table 52. Bio-Synthesis Corporation Information
Table 53. Bio-Synthesis Description and Major Businesses
Table 54. Bio-Synthesis Product Features and Attributes
Table 55. Bio-Synthesis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Bio-Synthesis Revenue Proportion by Product in 2024
Table 57. Bio-Synthesis Revenue Proportion by Application in 2024
Table 58. Bio-Synthesis Revenue Proportion by Geographic Area in 2024
Table 59. Bio-Synthesis Peptide Modification Service SWOT Analysis
Table 60. Bio-Synthesis Recent Developments
Table 61. Thermo Fisher Scientific Corporation Information
Table 62. Thermo Fisher Scientific Description and Major Businesses
Table 63. Thermo Fisher Scientific Product Features and Attributes
Table 64. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 66. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 67. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 68. Thermo Fisher Scientific Peptide Modification Service SWOT Analysis
Table 69. Thermo Fisher Scientific Recent Developments
Table 70. Syd Labs Corporation Information
Table 71. Syd Labs Description and Major Businesses
Table 72. Syd Labs Product Features and Attributes
Table 73. Syd Labs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Syd Labs Revenue Proportion by Product in 2024
Table 75. Syd Labs Revenue Proportion by Application in 2024
Table 76. Syd Labs Revenue Proportion by Geographic Area in 2024
Table 77. Syd Labs Peptide Modification Service SWOT Analysis
Table 78. Syd Labs Recent Developments
Table 79. JPT Corporation Information
Table 80. JPT Description and Major Businesses
Table 81. JPT Product Features and Attributes
Table 82. JPT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. JPT Recent Developments
Table 84. LifeTein Corporation Information
Table 85. LifeTein Description and Major Businesses
Table 86. LifeTein Product Features and Attributes
Table 87. LifeTein Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. LifeTein Recent Developments
Table 89. Creative Peptides Corporation Information
Table 90. Creative Peptides Description and Major Businesses
Table 91. Creative Peptides Product Features and Attributes
Table 92. Creative Peptides Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Creative Peptides Recent Developments
Table 94. Elabscience Corporation Information
Table 95. Elabscience Description and Major Businesses
Table 96. Elabscience Product Features and Attributes
Table 97. Elabscience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Elabscience Recent Developments
Table 99. Genosphere Biotechnologies Corporation Information
Table 100. Genosphere Biotechnologies Description and Major Businesses
Table 101. Genosphere Biotechnologies Product Features and Attributes
Table 102. Genosphere Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Genosphere Biotechnologies Recent Developments
Table 104. ProSci Corporation Information
Table 105. ProSci Description and Major Businesses
Table 106. ProSci Product Features and Attributes
Table 107. ProSci Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. ProSci Recent Developments
Table 109. Giotto Biotech Corporation Information
Table 110. Giotto Biotech Description and Major Businesses
Table 111. Giotto Biotech Product Features and Attributes
Table 112. Giotto Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Giotto Biotech Recent Developments
Table 114. SB-PEPTIDE Corporation Information
Table 115. SB-PEPTIDE Description and Major Businesses
Table 116. SB-PEPTIDE Product Features and Attributes
Table 117. SB-PEPTIDE Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. SB-PEPTIDE Recent Developments
Table 119. Biomatik Corporation Information
Table 120. Biomatik Description and Major Businesses
Table 121. Biomatik Product Features and Attributes
Table 122. Biomatik Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Biomatik Recent Developments
Table 124. allele life sciences Corporation Information
Table 125. allele life sciences Description and Major Businesses
Table 126. allele life sciences Product Features and Attributes
Table 127. allele life sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. allele life sciences Recent Developments
Table 129. Synpeptide Corporation Information
Table 130. Synpeptide Description and Major Businesses
Table 131. Synpeptide Product Features and Attributes
Table 132. Synpeptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Synpeptide Recent Developments
Table 134. Omizzur Corporation Information
Table 135. Omizzur Description and Major Businesses
Table 136. Omizzur Product Features and Attributes
Table 137. Omizzur Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Omizzur Recent Developments
Table 139. KMD Bioscience Corporation Information
Table 140. KMD Bioscience Description and Major Businesses
Table 141. KMD Bioscience Product Features and Attributes
Table 142. KMD Bioscience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. KMD Bioscience Recent Developments
Table 144. Leadgene Biomedical Corporation Information
Table 145. Leadgene Biomedical Description and Major Businesses
Table 146. Leadgene Biomedical Product Features and Attributes
Table 147. Leadgene Biomedical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Leadgene Biomedical Recent Developments
Table 149. KenPeptide Corporation Information
Table 150. KenPeptide Description and Major Businesses
Table 151. KenPeptide Product Features and Attributes
Table 152. KenPeptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. KenPeptide Recent Developments
Table 154. CASLO Corporation Information
Table 155. CASLO Description and Major Businesses
Table 156. CASLO Product Features and Attributes
Table 157. CASLO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. CASLO Recent Developments
Table 159. TGpeptide Corporation Information
Table 160. TGpeptide Description and Major Businesses
Table 161. TGpeptide Product Features and Attributes
Table 162. TGpeptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. TGpeptide Recent Developments
Table 164. Boston Cellron Corporation Information
Table 165. Boston Cellron Description and Major Businesses
Table 166. Boston Cellron Product Features and Attributes
Table 167. Boston Cellron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. Boston Cellron Recent Developments
Table 169. Bio Basic Corporation Information
Table 170. Bio Basic Description and Major Businesses
Table 171. Bio Basic Product Features and Attributes
Table 172. Bio Basic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Bio Basic Recent Developments
Table 174. Raw Materials Key Suppliers
Table 175. Distributors List
Table 176. Market Trends and Market Evolution
Table 177. Market Drivers and Opportunities
Table 178. Market Challenges, Risks, and Restraints
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources


List of Figures
Figure 1. Peptide Modification Service Product Picture
Figure 2. Global Peptide Modification Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. N-Terminal Modifications Product Picture
Figure 4. C-Terminal Modifications Product Picture
Figure 5. Fluorescence Dye Labeling Product Picture
Figure 6. Phosphorylation Product Picture
Figure 7. Others Product Picture
Figure 8. Global Peptide Modification Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Commercial
Figure 10. Academic Research
Figure 11. Peptide Modification Service Report Years Considered
Figure 12. Global Peptide Modification Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 14. Global Peptide Modification Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Peptide Modification Service Revenue Market Share by Region (2020-2031)
Figure 16. Global Peptide Modification Service Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. N-Terminal Modifications Revenue Market Share by Player in 2024
Figure 19. C-Terminal Modifications Revenue Market Share by Player in 2024
Figure 20. Fluorescence Dye Labeling Revenue Market Share by Player in 2024
Figure 21. Phosphorylation Revenue Market Share by Player in 2024
Figure 22. Others Revenue Market Share by Player in 2024
Figure 23. Global Peptide Modification Service Revenue Market Share by Type (2020-2031)
Figure 24. Global Peptide Modification Service Revenue Market Share by Application (2020-2031)
Figure 25. North America Peptide Modification Service Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Peptide Modification Service Revenue (US$ Million) in 2024
Figure 27. North America Peptide Modification Service Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Peptide Modification Service Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Peptide Modification Service Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Peptide Modification Service Revenue (US$ Million) in 2024
Figure 34. Europe Peptide Modification Service Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Peptide Modification Service Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 37. France Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Peptide Modification Service Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Peptide Modification Service Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Peptide Modification Service Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Peptide Modification Service Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 49. India Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Peptide Modification Service Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Peptide Modification Service Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Peptide Modification Service Revenue (US$ Million) in 2024
Figure 57. Central and South America Peptide Modification Service Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Peptide Modification Service Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Peptide Modification Service Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Peptide Modification Service Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Peptide Modification Service Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Peptide Modification Service Revenue (US$ Million) in 2024
Figure 63. South America Peptide Modification Service Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Peptide Modification Service Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Peptide Modification Service Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Peptide Modification Service Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Peptide Modification Service Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Peptide Modification Service Revenue (2020-2025) & (US$ Million)
Figure 69. Peptide Modification Service Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit